[ad_1]
In Chile, according to the Institute of Public Health (ISP), there are about 3 thousand people with different types of multiple sclerosis (MS), a disease that is also developing in men and women, and the peak of his presentation is at age 24.
The most common disease among patients is recurrent remittent . And the sanitary body approved a therapeutic equivalent of Synthon Chile Laboratory, whose active ingredient is Glatiramer acetate and will be used to treat it in its initial phase . It would be marketed from September
Glatiramer Acetate is a solution for injection presented in a pre-filled syringe of 40mg / 1mL. It is distinguished by altering the immune response of the central nervous system, inflammation, demyelination and axonal loss, which reduces the number of relapses in patients with relapsing recurrent MS who has the disease. approval of the European Medicines Agency (EMA). ] Multiple sclerosis is caused by a defect in the immune system in which the body catches itself, injuring the myelin sheath, the material that surrounds and protects the nerve cells.
As a result, some areas of the brain and spinal cord become inflamed, blocking messages between the two parties, producing symptoms of the disease that can be very diverse, depending on the area of the central nervous system affected.
Source link
